Use of TGF-BETA antagonists to treat infants at risk of developing bronchopulmonary dysplasia

A TGF-, dysplasia technology, applied in the direction of medical preparations containing active ingredients, anti-animal/human immunoglobulin, antibody medical components, etc., can solve the problem of reducing the incidence of disease

Inactive Publication Date: 2015-05-27
GENZYME CORP +1
View PDF78 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Utilization of surfactant therapy and other advanced treatments improves neonatal survival without concomitant reduction in BPD incidence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of TGF-BETA antagonists to treat infants at risk of developing bronchopulmonary dysplasia
  • Use of TGF-BETA antagonists to treat infants at risk of developing bronchopulmonary dysplasia
  • Use of TGF-BETA antagonists to treat infants at risk of developing bronchopulmonary dysplasia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] The present invention provides methods of treating infants at risk of developing bronchopulmonary dysplasia (BPD) or already suffering from BPD, including premature infants, at at least one point in time during the perinatal period, including the prenatal and postnatal periods, A therapeutically effective amount of a TGF-beta antagonist is administered to an infant during the perinatal period, including the prenatal and postpartum periods. As used herein, the term "infant" includes a human in utero or postpartum from about 24 weeks gestation to about 6 months postpartum.

[0026] bronchopulmonary dysplasia

[0027] The clinical diagnosis of BPD was made at 36 weeks' gestation in any premature infant with lung disease requiring continuous or continuous supplemental oxygen and those with abnormal chest x-rays. As used herein, "BPD" also includes all alternative definitions of clinical diagnosis, such as those made in infants older than four weeks, with persistent lung d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and / or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.

Description

[0001] This application is a divisional application of PCT application PCT / US2007 / 021234 filed on October 3, 2007, entitled "Use of TGF-β antagonists for the treatment of infants at risk of suffering from bronchopulmonary dysplasia", said PCT The date for the application to enter the Chinese national phase is June 3, 2009, and the application number is 200780044749.4. [0002] This application claims priority to US Provisional Application No. 60 / 827,933, filed October 3, 2006, which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates to the use of TGF-beta antagonists for the treatment of infants at risk of developing bronchopulmonary dysplasia, including premature infants. Background technique [0004] Babies born at a very early stage of development often suffer from respiratory failure due to their underdeveloped lungs, primitive respiratory drive and susceptibility to infection. Bronchopulmonary dysplasia (BPD), a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K45/06A61P11/00
CPCA61K2039/505C07K16/22A61P11/00A61K39/3955A61K45/06A61K9/0019A61K9/0073A61K9/12C07K2317/76
Inventor J·B·施特赖桑德J·D·小罗伯茨
Owner GENZYME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap